Anxiety is a result of a combination of biological, psychological, and other individual factors. Neurochemical imbalances in γ-aminobutyric acid (GABA), serotonin, dopamine, epinephrine, and other neurotransmitter pathways in the brain can contribute to the development of anxiety. For example, serotonin appears to be specifically involved in feelings of well-being, and disruption in this pathway is highly related to anxiety and depression.
Current treatments of anxiety have significant issues related to patient tolerability, dependency, and other negative side effects in patients. This has driven us to discover and develop pharmaceutical formulation (MP-20X) containing natural and chemical API molecules, targeting endocannabinoid system, that holds great potential in the field of pain management.